A recent study linked the action of two proteins found in the mammalian brain to provide a better understanding of how the brain regulates the activity of neurons to protect them from damage. That discovery could one day lead to new therapies for conditions such as stroke and epilepsy.
Newly formed Galecto Biotech AB is taking a distinctive approach to inhibiting galectin-3, a newly emerging target in several disease areas, and to tackling idiopathic pulmonary fibrosis (IPF) as its lead indication.
LONDON – The gene therapy Glybera has been rejected for the third time, despite the fact that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) last week voted 16 to 15 in favor of approving the treatment for ultrarare inherited disorder lipoprotein lipase deficiency.
In a second round of job cuts inside 12 months, Addex Therapeutics SA is seeking around 28 redundancies from its work force and is planning to intensify its use of outsourced R&D services.
LONDON – MRC Technology Ltd., the technology transfer arm of the UK Medical Research Council (MRC), is now making its commercialization services available to medical charities, in a move it hopes will improve translation of the £1 billion-plus (US$ 1.6 billion) per annum they spend on research.
• Cardio3 Biosciences SA, of Mont-Saint-Guibert, Belgium, received good manufacturing practice certification for its production facilities in Mont-Saint-Guibert from the Federal Agency for Medicines and Health Products of Belgium.
Shares in TiGenix NV gained 5 percent Tuesday on news that Cx611, its adult stem cell therapy for rheumatoid arthritis (RA), hit a key safety milestone in a Phase IIa safety trial.
Shire plc pumped up its regenerative medicine business by acquiring all but the oncology assets of privately held Pervasis Therapeutics Inc., which is developing an endothelial cell-based technology, in a deal valued at up to $200 million.
LONDON – The European Medicines Agency (EMA) has set out new rules on clinical trials conducted outside Europe and said it will reject any data from studies that do not meet those standards.
LONDON – A meta-analysis of several genomewide association studies has identified variants in 56 genetic loci related to bone mineral density, 14 of which increase the risk of bone fracture.
RSS